CRISPR Cancer Treatment: ERC Grant Fuels New Research

The race to develop truly targeted cancer therapies just received a significant boost. A Wageningen University & Research team, led by microbiologist John van der Oost, has secured €150,000 in ERC Proof of Concept funding to refine a novel CRISPR-based approach that aims to selectively destroy cancer cells by exploiting a fundamental difference in their DNA structure. This isn’t just another CRISPR story; it’s a move towards precision oncology that could sidestep the brutal side effects of traditional treatments – a long-sought goal in the field.

The Deep Dive: Beyond Standard CRISPR

CRISPR-Cas9 has revolutionized gene editing, but its application in cancer therapy has been hampered by off-target effects – unintended edits to healthy cells. This new approach, building on the discovery of ThermoCas9 in a compost heap bacterium, represents a significant departure. The key lies in DNA methylation. Cancer cells often exhibit a disrupted methylation pattern compared to healthy cells, essentially losing some of these crucial “tags.” ThermoCas9 is uniquely equipped to recognize this difference. While standard CRISPR acts like molecular scissors indiscriminately cutting DNA, ThermoCas9 acts more like a guided missile, specifically targeting cells with fewer methyl groups. This isn’t the first attempt to exploit epigenetic differences in cancer, but the specificity of ThermoCas9 offers a potentially game-changing advantage. The focus on liver cancer is strategic; the liver’s natural role in filtering the bloodstream allows for efficient delivery of CRISPR components via nanoparticles, a delivery challenge that has plagued other gene therapy efforts.

The Forward Look: Hurdles and the Path to Clinical Trials

Despite the promising lab results, significant challenges remain. The “genetically messy” nature of tumors – the fact that methylation patterns aren’t uniformly disrupted within a single tumor, and can even vary between cells – means this therapy won’t be a silver bullet. Some cancer cells will inevitably escape detection, and there’s a risk of off-target effects, albeit potentially lower than with conventional CRISPR. The team’s immediate focus on optimizing ThermoCas9 for body temperature is critical; its current high-temperature requirement renders it impractical for in vivo applications. Expect to see increased collaboration with cancer specialists, potentially at institutions like the Netherlands Cancer Institute (NKI), as the project progresses. The ERC Proof of Concept grant is designed to bridge the gap between lab discovery and practical application, meaning the next 18 months will be crucial for demonstrating scalability and safety. A key indicator of success will be the team’s ability to consistently induce cell death in a wider range of cancer cell lines and, ultimately, in animal models. While clinical trials are still years away, this research represents a compelling step towards a future where cancer treatment is defined by precision, not just brute force. The broader trend of leveraging epigenetic vulnerabilities in cancer is gaining momentum, and Wageningen’s work with ThermoCas9 positions them at the forefront of this exciting field.